데이터 상품 상세검색

[감염병특허]

FDA 승인물질 등장 특허 원문 텍스트 (미국특허)

FDA 승인물질 등장 특허 원문 텍스트 (미국특허)

  • 등록일2023-07-20
  • 조회수184
  • 다운로드55
  • 카테고리감염병특허
  • 0

데이터 기본 이용료

  • 500,000원
상세정보
데이터등록일 데이터 수정일 데이터 이용기한 판매제공처
2023-07-20 2023-08-23 무기한 BLT
데이터 제공포맷 데이터 제공방식 데이터 파일용량 데이터 상품구분
csv/zip 다운로드 1.58 GB dataset

■ 데이터상품설명 FDA 승인물질의 상품명, 성분명을 기준으로 질병별로 정리된 특허데이터를 가공해 제공합니다. 본 데이터 상품은 원문에 가까운 데이터의 제공이 목적이며, 질병/특허번호/날짜/권리자/명칭/초록 등의 정보가 수록되어있습니다. ■ 간략 통계 수록 물질: 약 4730종 (상품명 2829종, 성분명 1709종, 천연물질 192종) 수록 특허수: 약 21.6만건 (2023년 02월 현재기준) 물질당 특허수 :평균 300건 (최소1 최대 10221건) ■ 데이터 내용설명 아래와 같은 데이터를 포함하고 있습니다 1) 물질정보 (물질명 또는 성분명) 2) 특허번호정보 (특허ID/출원번호/등록번호) 3) 특허날짜정보 (출원일자/등록일자) 4) 특허권리자 5) 특허원문 (발명의명칭/초록) ■ 참고: 상품명과 성분명 상품명: viagra(비아그라), tamiflu(타미플루) 성분명: sildenafil citrate, oseltamivir phosphate

샘플정보
컨텐츠ID
컨텐츠영어명
컨텐츠한국어명
컨텐츠대분류명
질병분류코드
MESH분류코드
국가코드
특허ID
특허출원번호
특허공개번호
특허등록번호
특허출원일자
특허출원공개일자
특허등록일자
특허최초공보발행일자
현재특허권리자그룹
특허발명의명칭제목
특허초록
메인CPC특허분류코드
전체CPC특허분류코드목록
CPC특허분류코드개수
메인IPC특허분류코드
전체IPC특허분류코드목록
IPC특허분류코드개수
301880 nasalcrom [cromolyn sodium] nasalcrom [cromolyn sodium] FDA 승인상품명 US US00005858996B 08/863855 5858996 19970527 19990112 19990112 Novartis Pharma Compositions and methods for stabilizing polymers <p>Compositions and methods for reducing the decomposition rate of polymeric bioadhesives and viscosity enhancers, such as poly(acrylic acids). The compositions include at least one strong, stable chelating agent, preferably an organophosphorous compound such as diethylene triamine penta(methylene phosphonic acid). These biocompatible compositions are especially useful in the ophthalmic field.</p> A61K9/0048 A61K9/0048|A61P27/02|C08K5/5317 3 A01N57/00 A01N57/00|A61K47/24|A61K9/08|C08K5/5317|A61K9/00 5
301881 nasalide; nasarel [flunisolide] nasalide; nasarel [flunisolide] FDA 승인상품명 US US00006042811B 08/214763 6042811 19940316 20000328 20000328 3M Innovative Properties Aerosol formulation containing a diol-diacid derived dispersing aid <p>A medicinal aerosol formulation containing a particulate drug and a diol/diacid condensate as a dispersing aid.</p> A61K9/008 A61K9/008 1 A61K9/12 A61K9/12|A61K47/14|A61K9/00|A61K9/72|A61K47/34 5
301899 nembutal [pentobarbital] nembutal [pentobarbital] FDA 승인상품명 US US00004101549B 05/690123 4101549 19760526 19780718 19780718 F. Hoffmann-La Roche Aminophenyl esters of 5-carboxyalkyl barbituric acids <p>Aminoaryl esters and amino-lower alkyl amides of carboxy substituted barbiturates are linked via an amide linkage to carboxylated latex polymers to form reagents which are useful in a sensitive diagnostic test to detect the presence of barbiturates in body fluids. !&lt;P&gt;&lt;P&gt; The large increase in the abuse of therapeutic agents, particularly the barbiturates, by the general population as well as military personnel, has brought with it a substantial need to improve analytical techniques for the determination of such agents in biological fluids. In many instances, medical treatment centers are faced with the immediate need for determining the identity of a barbiturate taken by a patient who is unable, being in a comatose condition, or unwilling to supply such information to the treating physician. Early procedures involved the identification of barbiturates by extraction and thin-layer, gas chromatographic and spectrophotometric methods. These techniques have the disadvantages of being relatively time-consuming, laborious and lacking great sensitivity. Recently, a rapid and sensitive immunoassay procedure involving the reaction between antibodies and barbiturate antigen was described by S. Spector in U.S. Pat. No. 3,766,162 and by S. Spector and E. J. Flynn in Science, 174, 1037 (1971). This procedure, however, requires sophisticated and expensive equipment, such as scintillation counters. Therefore, it would be desirable to develop a rapid and highly sensitive assay for detecting the presence of barbiturates in biological fluids which would not require sophisticated equipment and could be easily performed on site by laboratory technicians having a minimum of training.&lt;P&gt;&lt;P&gt;BRIEF DESCRIPTION OF THE INVENTION&lt;P&gt;&lt; P&gt;The present invention relates to a novel class of barbiturate derivatives, namely, aminoaryl esters and amino- lower alkyl amides of carboxy substituted barbiturates, which esters and amides may be covalently coupled via an amide linkage to a carboxylated latex polymer. The barbiturate thus linked to the latex polymer by means of the linking group can then be utilized as a reagent in a sensitive diagnostic assay for the presence of barbiturates in biological fluids. This assay method is dependent upon the well known binding of antigen to antibodies specific therefor, which is manifested by an insolubilization or agglutination followed by flocculation. When either the antigen or the antibody is linked to a suitable polymer such as a latex polymer, as hereinafter described, the detection of the antigen-antibody binding by means of agglutination is significantly enhanced by means of the latex so that such agglutination reaction is easily visualized by the naked eye. &lt;P&gt;&lt;P&gt;The general technique of utilizing latex particles as carriers for antigens or antibodies for easy visualization of the antigen- antibody reaction has been previously described in the literature, for example, U.S. Pat. No. 3,857,931.&lt;P&gt;&lt;P&gt; The starting materials which are used for the preparation of the latex reagents of the present invention are aminoaryl esters and amino-lower alkyl amides of carboxy substituted barbiturates. As used herein, the expression lower alkyl is meant to include straight and branched-chain saturated hydrocarbon radicals having from 2 to 8 carbon atoms, inclusive, such as ethyl, propyl, n-butyl, iso-butyl and the like. The term aryl denotes an aromatic radical derived from an unsubstituted or substituted arene and includes phenyl, naphthyl, halophenyl, tolyl, anisyl, nitrophenyl, hydroxyphenyl and the like. The term halide denotes iodide, bromide and chloride.&lt;P&gt;&lt;P&gt;The barbiturates useful for binding to latex polymers are those having free carboxylic acid groups. The barbiturate of particular preference in the practice of the present invention is 5-allyl- 5-(1-carboxy-isopropyl)barbituric acid (allonalcarboxylic acid) since it has a carboxylic acid group in the sidechain and is readily obtainable. Thus, particularly preferred reagents are aminoaryl esters and amino- lower alkyl amides of the carboxylic acid group of allonalcarboxylic acid. However, the present assay, as hereinafter described, will detect barbiturates with or without free or functionalized carboxylic acid groups, such as barbital, phenobarbital, amobarbital, butabarbital, pentobarbital, etc.&lt;P&gt;&lt;P&gt;The aminoaryl esters and amino-lower alkyl amides of carboxy substituted barbiturates, as described above, are conveniently prepared from carboxy substituted barbiturates. Using allonalcarboxylic acid as an example, one can conveniently introduce the requisite aminoaryl or the amino-lower alkyl moiety by methods well known in the art. Thus, for the preparation of aminoaryl esters of the carboxy substituted barbiturates, one can esterify allonalcarboxylic acid with, for example, p-nitrophenol to afford 5-allyl-5-(1-p- nitrophenyloxycarbonyl-isopropyl)barbituric acid which one can then reduce to 5-propyl-5-(1-p-aminophenyloxycarbonyl-isopropyl) barbituric acid.&lt;P&gt;&lt;P&gt; The esterification is performed in the presence of a condensing agent dissolved in an inert organic solvent. Suitable condensing agents include carbodiimides such as N,N'- diphenylcarbodiimides and N,N'-dicyclohexylcarbodiimides. Suitable inert organic solvents include polar aprotic solvents such as N,N- dimethylformamide, dimethylsulfoxide and hexamethylphosphoramide alone or admixed with non-polar aprotic solvents such as acetone, acetonitrile and ethyl acetate. A particularly preferred condensing agent is N,N'- dicyclohexylcarbodiimide and a particularly preferred organic solvent system is N,N-dimethylformamide-ethyl acetate.&lt;P&gt;&lt;P&gt;The temperature of the esterification reaction is not narrowly critical. The reaction may be carried out between about 0&deg; and 50&deg; C., most preferably at about 0&deg; to 25&deg; C.&lt;P&gt;&lt;P&gt;The reduction is performed by treating the nitroester, so obtained, dissolved in a suitable inert organic solvent, preferably an alkanol such as methanol, ethanol, or 2-propanol, with hydrogen in the presence of a suitable hydrogenation catalyst until the cessation of the uptake of hydrogen. Included among suitable hydrogenation catalysts are platinum, palladium, rhodium, ruthenium and nickel, unsupported or supported on carriers such as carbon, silica, alumina and the like. A particularly preferred hydrogenation catalyst is 10% palladium-on-carbon. While the temperature and pressure at which the hydrogenation is accomplished is not critical, it is preferred to carry out the reaction at about room temperature and about atmospheric pressure.&lt;P&gt;&lt;P&gt;For the preparation of amino- lower alkyl amides of carboxy substituted barbiturates, one can aminate allonalcarboxylic acid with, for example, 1, 4-diaminobutane to afford 5- allyl-5- 1-(4-aminobutylcarbamoyl)- isopropyl!barbituric acid.&lt;P&gt; &lt;P&gt;The amination is performed in the presence of a condensing agent dissolved in an inert organic solvent. Suitable condensing agents include carbodiimides such as N,N'- diphenylcarbodiimide and N,N'- dicyclohexylcarbodiimide and carbonyldiimidazoles such as 1,1'- carbonyldiimidazole. Suitable inert organic solvents are ethereal solvents such as monoglyme, diglyme, dioxane and tetrahydrofuran. A particularly preferred condensing agent is 1,1'-carbonyldiimidazole. A particularly preferred inert organic solvent is tetrahydrofuran.&lt;P&gt; &lt;P&gt; The temperature at which the amination is carried out is not narrowly critical. A reaction temperature within the range of about 0&deg; to about the boiling point of the solvent is preferred, a reaction temperature of about 25&deg; C. being most preferred.&lt;P&gt;&lt;P&gt; The carboxy substituted barbiturates are also conveniently prepared by methods well known to a chemist of ordinary skill in the art. For example, the carboxy substituted barbiturates can be readily prepared by reductive alkylation of barbituric acid with an aldehydo- or keto-ester followed by alkylation and saponification of the ester group of the resulting 5,5-disubstituted-barbituric acid.&lt;P&gt; &lt;P&gt;The reductive alkylation is conducted by treating barbituric acid and an aldehydo- or keto-ester such as ethyl formylacetate, ethyl acetoacetate and ethyl levulinate, with hydrogen in the presence of a metal hydrogenation catalyst to afford a 5-monosubstituted barbituric acid derivative. Suitable metal catalysts are nickel and the nobel metals such as platinum, palladium, rhodium, ruthenium and so forth. The catalysts are normally employed in finely divided form and may be either unsupported or present on a suitable inert carrier such as carbon, aluminum, silica, calcium carbonate and the like. A particularly preferred catalyst is 10% palladium-on-carbon.&lt;P&gt;&lt;P&gt;As solvents for the reductive alkylation, there may be mentioned alcohols such as methanol, ethanol, 2-propanol and the like, and esters such as ethyl acetate and so forth.&lt;P&gt;&lt;P&gt;While the reductive alkylation may be performed over a wide range of temperatures and pressures from, for example, about room temperature to about 150&deg; C. and about atmospheric pressure to about 1000 psi, it is preferable to employ a reaction temperature of about 90&deg; to about 100&deg; C. and a pressure of about 700 psi.&lt;P&gt;&lt;P&gt;The alkylation step is accomplished by treating the monosubstituted barbituric acid derivative with an alkylating agent such as methyl halide, propyl halide, allyl halide, hexyl halide, cyclohexenyl halide and the like, in a suitable inert solvent in the presence of a base to afford a 5,5-disubstituted barbituric acid derivative. Suitable solvents include, among others, alcohols such as methanol, ethanol, 2-propanol and the like, water and mixtures of water and alcohols. Suitable bases are alkali metal and alkaline earth hydroxides such as sodium and potassium hydroxide and calcium hydroxide, and alkali metal alkoxides such as sodium methoxide, potassium ethoxide and potassium tertiary-butoxide. A particularly preferred base and solvent system is about 20% aqueous sodium hydroxide. The alkylation may be conducted over a temperature range of from about 10. degree. to about 80&deg; C., most preferably between about 25&deg; to 60&deg; C.&lt;P&gt;&lt;P&gt;The saponification step is conducted by treating the disubstituted barbituric acid derivative with an aqueous acid such as hydrochloric acid, hydrobromic acid, dilute sulfuric acid and the like, at an elevated temperature. For this conversion, aqueous hydrochloric acid having a normality of about 1 and a reaction temperature of about the reflux temperature of the reaction mixture is preferred.&lt;P&gt;&lt;P&gt;In order to prepare the diagnostic reagent useful for the practice of the present invention, aminoaryl esters and amino-lower alkyl amides of carboxy substituted barbiturates are covalently bonded by means of an amide linkage to a latex polymer containing carboxyl groups.&lt;P&gt;&lt;P&gt;Suitable latex polymers for this purpose are carboxylated styrene butadienes, carboxylated polystyrenes, acrylic acid polymers and the like. Among the commercial latex polymers which are included in the aforementioned classes are Dow 421, Dow 816, Dow 620, Fluka 241 and Dow 241. Dow batch 1721, a latex polymer of the polystyrene type having a particle size of about 0.2 to about 0.3 microns, percent solid composition of about 8 to about 12% and a specific gravity of about 1.02, is also suitable.&lt;P&gt;&lt;P&gt; Particularly preferred polymers are carboxylated styrene butadiene copolymers, preferably Fluka 241 or Dow 241. Suitable latex carrier particles are generally supplied commercially as an aqueous latex suspension, usually in concentrations of about 5 to about 60% solids. These polymers are water insoluble, have a particle size in the range from about 0.01 to about 0.9 microns, preferably between about 0.1 and about 0.3 microns, and a specific gravity near that of water enabling them to remain in aqueous suspension. The particles should have sufficient surface charge density so that when coupled to the aminoaryl esters and amino-lower alkyl amides of carboxy substituted barbiturates, their repulsive forces are enough to prevent aggregation.&lt;P&gt;&lt; P&gt;The aminoaryl esters and amino-lower alkyl amides of carboxy substituted barbiturates are coupled to the carboxylated latex polymers by means of an amide linkage initiated in the presence of a water soluble carbodiimide condensing agent. The degree of coupling is dependent upon the density of the reactive groups in the polymer. The density of the reactive groups is not critical to the operability of this invention, as long as a sufficient number of reactive groups are present to provide coupling of a sufficient amount of barbiturate moiety to be useful in a diagnostic test. However, a suitable density would be in the range of from about 1 to about 5%, preferably about 3%, by weight. The coupling reaction with carbodiimides is described in detail in U.S. Pat. No. 3,857, 931.&lt;P&gt;&lt;P&gt;Once the latex coupled product is formed, it can be utilized in specific diagnostic tests for the detection of barbiturates. It can be used in any convenient concentration, depending upon the specific test and samples involved. However, concentrations of from about 0.1 to about 2% by weight of latex solids are suitable and the preferred concentrations are from about 0.3 to about 1.5% by weight.&lt; P&gt; &lt; P&gt;In a typical test, a measured amount of antiserum against barbiturates is mixed with a barbiturate free body fluid, for example, serum, saliva or urine. Then, a measured amount of aminoaryl or amino- lower alkyl barbiturate coupled latex is added and the mixture is allowed to incubate at a slightly elevated temperature, e.g., 37&deg; C., for a period of time, for example, from about 1 to about 3 hours, preferably for about 2 hours. The pH of the text mixture is suitably in the range of from about pH 5.0 to 8.5, most preferably about 6.5 to 7.5. After the incubation, flocculation or agglutination of the latex particles is noted. The concentration and quantity of both the antiserum and the latex complex are adjusted to produce a strong flocculation, and the minimum concentrations of both reagents which produce a strong flocculation are determined. The mixture of antiserum against barbiturate and barbiturate free body fluid may be incubated at a slightly elevated temperature, e.g., 37&deg; C., prior to the addition of the aminoaryl or amino-lower alkyl barbiturate coupled latex.&lt;P&gt;&lt;P&gt;The antisera which may be used in the present diagnostic test are antisera specific for barbiturates, such as secobarbital and pentobarbital. The preparation of such antisera is described in U.S. Pat. No. 3,766,162 and in Science, 174, 1037 (1971).&lt;P&gt;&lt;P&gt;After the control system is set up, as described above, various amounts of barbiturates, e.g., secobarbital, pentobarbital, butabarbital, amobarbital, phenobarbital and barbital are dissolved in barbiturate free body fluid. The minimum amount of barbiturate required to inhibit the flocculation is noted. This quantity will depend both upon the concentration and the amount of body fluid added, as well as upon the concentration and the strength of the antiserum utilized in the test.&lt;P&gt; &lt;P&gt;In a preferred test, the quantities and concentrations are adjusted so that approximately 400- 500 microliters of serum or urine containing between about 100 and 200 nanograms of barbiturate per milliliter (total of between 40-50 and 80- 100 nanograms of barbiturate) will be just sufficient to inhibit flocculation. Once the test has been standardized with one type of body fluid, for example, urine, another type of body fluid, for example, serum, should not be substituted, and a separate standard must be set up for this.&lt;P&gt;&lt;P&gt;Since the presence of flocculation is easily visualized by the naked eye, the present test serves as an extremely sensitive assay method for the detection of barbiturates, such as secobarbital, pentobarbital, butabarbital, amobarbital, phenobarbital and barbital. Thus, once the test has been standardized as mentioned above, the presence of nanogram quantities of these barbiturates in body fluids can easily be detected by noting the inhibition of flocculation caused by the presence of such barbiturates in the body fluid, as compared with the flocculation resulting when barbiturate free body fluid is employed.&lt; P&gt;&lt;P&gt;The test can be standardized so that a medically and statistically meaningful cut-off point is established. Thus, quantities of barbiturates in body fluid greater than this amount will cause inhibition of flocculation (a positive test for the presence of such drug in the body fluid) and quantities less than this amount will not inhibit flocculation (a negative test).&lt;P&gt;&lt;P&gt;The above described reagents can be conveniently packaged for commercial purposes, e.g., in a diagnostic reagent kit containing two separate containers: one with the antiserum against barbiturates and the other with the aminoaryl esters or amino-lower alkyl amides of carboxy substituted barbiturates bonded via an amide linkage to latex particles containing carboxyl groups, most preferably in aqueous suspension.&lt;P&gt;&lt;P&gt;The aminoaryl esters and amino-lower alkyl amides of carboxy substituted barbiturates can also be linked to immunogenic carrier materials such as proteins or polypeptides by means of an amide linkage to afford antigens which are useful for the elicitation of antibodies specific for barbiturates. The method of linkage to immunogenic carrier materials, as well as the elicitation of antibodies, are generally described in U.S. Pat. No. 3,766, 162.&lt;P&gt;&lt;P&gt;The invention is further explained and illustrated in the following examples. All temperatures are in degrees Centigrade.</p> G01N33/948 G01N33/948|Y10T436/147777|C07D239/62 3 C07D239/62 C07D239/62|G01N33/53|G01N33/94|C07D239/64|G01N33/52 5
300071 afinitor [everolimus] afinitor [everolimus] FDA 승인상품명 US US00011406623B2 17/509939 20220040155 11406623 20211025 20220210 20220809 20220210 GW Research Methods of treating tuberous sclerosis complex with cannabidiol and everolimus The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus. A61P25/08 A61P25/08|A61K31/436|A61K2236/39|A61K2236/51|A61K2236/37|A61K36/185|A61K31/05|A61K2236/17|A61K2236/333|A61P43/00|A61K2236/15|A61K2236/53 12 A61K36/00 A61K36/00|A61K31/436|A61K31/05|A61K36/185 4
301883 nasonex [mometasone furoate] nasonex [mometasone furoate] FDA 승인상품명 US US00007605151B2 12/051434 20080234242 7605151 20080319 20080925 20091020 20080925 Nicox Nitrate esters of corticoid compounds and pharmaceutical applications thereof Compounds of the formula C07J43/00 C07J43/00|A61P29/00|A61P31/04|A61P19/02|A61P37/00|C07J41/005|C07J71/00|A61P1/00|A61P17/00 9 A61K31/56 A61K31/56|A61K31/58|A61P29/00|A61P37/00|C07J5/00|C07J71/00|A61K31/57|C07J41/00|A61P19/02 9
301882 nascobal [cyanocobalamin] nascobal [cyanocobalamin] FDA 승인상품명 US US00006159505B 08/945606 6159505 19980121 20001212 20001212 Piper; Edwina M. Compositions for the treatment of migraine, containing potassium, magnesium and pyridoxine <p>Compositions for the treatment and prevention of migraine or stress headaches wherein there is supplied a combination of potassium, magnesium and pyridoxine optionally in association with other nutrients and/or simple analgesics.</p> A61K33/06 A61K33/06 1 A61K31/4415 A61K31/4415|A61K33/14|A61K33/12|A61K33/10|A61K33/08|A61K33/00|A61K33/06 7
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US20110144005A1 12/963900 20110144005 20101209 20110616 20110616 Scynexis NOVEL CYCLIC PEPTIDES Compounds are disclosed of general formula (I): C07K7/645 C07K7/645|A61P1/16|A61K38/00|A61P43/00|A61P37/02|A61P31/14 6 A61K38/12 A61K38/12|A61P31/14|C07K7/64 3
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US00010709707B2 16/091830 20190201397 10709707 20170406 20190704 20200714 20190704 Oyster Point Pharma Methods of treating ocular conditions Described herein are methods and pharmaceutical formulations for treating ocular conditions. A61K31/506 A61K31/506|A61K38/13|A61K31/436|A61K9/0043|A61P27/04|A61K45/06 6 A61K31/506 A61K31/506|A61K9/00|A61K38/13|A61K31/436|A61P27/04|A61K45/06 6
301883 nasonex [mometasone furoate] nasonex [mometasone furoate] FDA 승인상품명 US US20050220717A1 11/061529 20050220717 20050222 20051006 20051006 3M Innovative Properties Steroid solution aerosol products with enhanced chemical stability A medicinal aerosol steroid solution formulation product with enhanced chemical stability. The steroid is a 20-ketosteroid having an OH group at the C-17 or C-21 position and the aerosol container has a non-metal interior surface which has been found to reduce chemical degradation of such steroids. A61K9/008 A61K9/008|A61K9/124|A61P1/02|A61K31/58|B65D83/54|A61K31/573|B65D83/38|A61K31/57|A61P11/06 9 A61L9/04 A61L9/04|A61M11/00 2
301884 natacyn [natamycin] natacyn [natamycin] FDA 승인상품명 US US00006655081B1 09/608186 6655081 20000630 20031202 20031202 Sylvan|Sylvan Bio Mushrooms <p>A substrate for mushroom cultivation comprises a polyene fungicide, in particular, natamycin. Mushrooms cultivated in such substrates can be harvested earlier than mushrooms cultivated in substrates which do not include polyene fungicides. Alternatively, mushrooms grown in a substrate comprising a polyene fungicide achieve a greater size than mushrooms grown for the same amount of time in a substrate which does not include a polyene fungicide.</p> C05G3/60 C05G3/60|A01G18/70|A01G18/50|A01G18/20 4 A01G1/04 A01G1/04|C05G3/02 2
301884 natacyn [natamycin] natacyn [natamycin] FDA 승인상품명 US US00008722134B2 12/518176 20100050299 8722134 20071206 20100225 20140513 20100225 Dsm IP Assets Post-harvest treatment of fruits with an antifungal composition The present invention relates to the treatment of wounds occurring from cutting bananas and pineapples from a tree with a composition containing natamycin and at least one phosphite containing compound. A23B7/155 A23B7/155|A23B7/157|A01N43/90 3 A01G5/06 A01G5/06|A01P7/04|A01P3/00|A01N43/90|A01H5/08|A01P5/00|A01P1/00 7
301884 natacyn [natamycin] natacyn [natamycin] FDA 승인상품명 US US00009468212B2 14/760276 20150351404 9468212 20140113 20151210 20161018 20151210 Dsm IP Assets Antifungal compositions The present invention relates to new antifungal compositions and their use in the treatment of agricultural products. A01N43/90 A01N43/90|A01N43/36 2 A01N43/90 A01N43/90|A01N43/36 2
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US20110297563A1 13/211673 20110297563 20110817 20111208 20111208 Sanofi METHODS FOR REDUCING RISK Methods for limiting and controlling the distribution of dronedarone to patients whose use of the drug might present an unacceptable risk. G09B19/00 G09B19/00|A61K31/343 2 B65D71/00 B65D71/00|G09B23/28 2
301884 natacyn [natamycin] natacyn [natamycin] FDA 승인상품명 US US20060257486A1 11/429736 20060257486 20060508 20061116 20061116 Novartis Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders Topical aqueous suspension compositions of sparingly soluble ophthalmic drugs are disclosed. The compositions comprise a combination of a poloxamine nonionic surfactant and a glycol tonicity-adjusting agent such as propylene glycol. A61K31/57 A61K31/57|A61P9/00|A61K9/10|A61K31/542|A61P29/00|A61K31/165|A61P27/06|A61K9/0048|A61P27/02 9 A61K9/14 A61K9/14 1
301889 natural estrogenic substance-estrone [estrone] natural estrogenic substance-estrone [estrone] FDA 승인상품명 US US20050271739A1 10/864744 20050271739 20040608 20051208 20051208 Wang, Xiang, H. Methods and compositions for accelerating alcohol metabolism A composition and method of using thereof for accelerating alcohol metabolism are provided. A61K35/55 A61K35/55|A23V2002/00|A61K36/064 3 A61K35/55 A61K35/55|A61K35/72 2
301886 natesto [testosterone] natesto [testosterone] FDA 승인상품명 US US00006761890B1 09/659983 6761890 20000912 20040713 20040713 Pepscan Systems Peptide, immunogenic composition and vaccine or medical preparation, a method to immunize animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine <p>A peptide that comprises a modified tandem GnRH decapeptide sequence which allows for a testosterone level that is essentially non-detectable after vaccination with the peptide in a suitable dosage and/or allows for a an immunogenic response that allows for the effective discrimination between GnRH-I and GnRH-II and a method for the immunocastration of pigs. </p> C07K7/23 C07K7/23|C07K14/723|A61K39/00 3 C07K14/59 C07K14/59|C07K17/00|A61K39/00|A61K38/24|C07K7/23|C07K14/72 6
301886 natesto [testosterone] natesto [testosterone] FDA 승인상품명 US US00006855836B2 09/963680 20020091112 6855836 20010927 20020711 20050215 20020711 Bayer Healthcare 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds The invention relates to 17-methylene steroids, process for their production and pharmaceutical compositions that contain these compounds. C07J13/00 C07J13/00 1 C07J13/00 C07J13/00|A61K31/56 2
301104 flunisolide [flunisolide] flunisolide [flunisolide] FDA 승인상품명 US US20110124683A1 12/779638 20110124683 20100513 20110526 20110526 Atopix Therapeutics Use of CRTH2 Antagonist Compounds The invention relates to compounds of general formula (I): A61K31/404 A61K31/404|A61P37/08 2 A61K31/405 A61K31/405|A61P37/08|A61K31/4709|A61K31/4439 4
301886 natesto [testosterone] natesto [testosterone] FDA 승인상품명 US US00007608643B2 11/370005 20060258699 7608643 20060307 20061116 20091027 20061116 MSD (Merck & Company) Compounds for inhibiting KSP kinesin activity The present invention relates to compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: A61K31/4743 A61K31/4743|A61K45/06 2 A01N35/04 A01N35/04|C07D417/00|C07D419/04|A61K31/541|A61K31/519|A61K31/4743|A61K31/12|A01N43/90 8
301918 neuramate [meprobamate] neuramate [meprobamate] FDA 승인상품명 US US20070231390A1 11/391739 20070231390 20060329 20071004 20071004 Andrx Labs Formulations including hygroscopic compounds The invention is directed to dosage forms suitable for the administration of hygroscopic active agents. A61K9/0004 A61K9/0004|A61K31/19|A61K9/2866 3 A61K9/24 A61K9/24 1
301886 natesto [testosterone] natesto [testosterone] FDA 승인상품명 US US00008865201B2 12/308786 20110091555 8865201 20070621 20110421 20141021 20110421 Polichem Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant in the manufacture of a medicament for treating female genital disorders a) at least one polyacrylic acid derivative in preferred amounts of 0.5-40%, A61K31/496 A61K31/496|A61P33/02|A61K9/0039|A61P33/00|A61P31/10|A61P31/02|A61P15/00|A61P15/02|A61K9/2054|A61P31/12|A61P31/04|A61P31/00 12 A61K9/00 A61K9/00|A61K9/52|A61K9/20|A61K31/496|A61P31/00|A61P15/02|A61K31/4418 7
301888 natroba [spinosad] natroba [spinosad] FDA 승인상품명 US US00008680121B2 13/285471 20120110701 8680121 20111031 20120503 20140325 20120503 Corteva Agriscience Pesticidal compositions and processes related thereto This document discloses molecules having the following formula (Formula One) A01N43/50 A01N43/50|C05C3/00|A01N47/18|A01N25/00|A61P33/14|A01N47/24|A61P33/00|C05G3/60|C07D401/04 9 A01N43/40 A01N43/40|A01N25/34|A01P7/00|C07D401/04|A01H5/10|A01P5/00|A01P7/04 7
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US20060122272A1 11/336846 20060122272 20060123 20060608 20060608 ZaCh System Stable gabapentin compositions Stable compositions containing gabapentin compositions, methods of preparing such compositions, and methods of using such compositions. A61K31/195 A61K31/195|A61P25/08|A61P25/28|A61P25/00|A61P25/22|A61K31/198|A61P25/20|A61P25/16 8 A61K31/195 A61K31/195 1
301886 natesto [testosterone] natesto [testosterone] FDA 승인상품명 US US20050233970A1 11/088462 20050233970 20050323 20051020 20051020 Praecis Pharmaceuticals Methods for treating long QT syndrome The present invention provides compositions and methods for treating QT prolongation in a subject in need thereof. The method comprises the step of administering to the subject a therapeutically effective amount of an agent which increases the androgen level of the subject. A61K38/09 A61K38/09|A61K31/55|A61B5/349|A61K31/56 4 A61K0/3809 A61K0/3809|A61K0/3156|A61K0/3155 3
301886 natesto [testosterone] natesto [testosterone] FDA 승인상품명 US US00010881670B2 16/727737 20200222426 10881670 20191226 20200716 20210105 20200716 Lipocine Oral testosterone tridecanoate therapy The present disclosure provides methods and compositions for testosterone replacement therapy. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a therapeutically effective amount of a testosterone ester while avoiding unacceptably high testosterone levels. A61K31/568 A61K31/568|A61K9/4858|A61P5/24|A61K9/48|A61K9/0053 5 A61K31/568 A61K31/568|A61P5/24|A61K9/48|A61K9/00 4
301886 natesto [testosterone] natesto [testosterone] FDA 승인상품명 US US00011103543B2 16/617280 20210128646 11103543 20180227 20210506 20210831 20210506 Kirin Holdings Composition for recovering from fatigue and/or preventing fatigue accumulation An object of the present invention is to provide a novel food material effective for recovering from fatigue and/or preventing fatigue accumulation. The present invention provides a composition for use in recovering from fatigue and/or preventing fatigue accumulation, comprising a <i>Lactococcus </i>bacterium as an active ingredient. A61P43/00 A61P43/00|A61K35/744|C12N1/20|A23L33/135|A23V2002/00 5 A61K35/744 A61K35/744|A23L33/135 2
301886 natesto [testosterone] natesto [testosterone] FDA 승인상품명 US US00011034715B2 16/720369 20200223882 11034715 20191219 20200716 20210615 20200716 Antengene Therapeutics Ectonucleotidase inhibitors and methods of use thereof The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention. C07H19/167 C07H19/167|A61P25/24|A61P29/00|A61P35/00|A61P37/00|C07H19/06|C07H19/16|A61P25/16 8 C07H19/167 C07H19/167|A61P35/00|A61P25/16|A61P37/00|A61P25/24|A61P29/00 6
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US20080293777A1 12/126834 20080293777 20080523 20081127 20081127 Sunesis Pharmaceuticals Weight Loss Treatment The present invention relates to the use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one and other selenium-containing compounds for weight loss. A61K8/58 A61K8/58|A61Q19/06|A61P3/04|A61K31/427|A61K31/41 5 A61K31/41 A61K31/41|A61K31/427|A61P3/04 3
301886 natesto [testosterone] natesto [testosterone] FDA 승인상품명 US US00011285111B2 16/268518 20190247314 11285111 20190206 20190815 20220329 20190815 Ricoh Particle-producing method and particle-producing apparatus A particle-producing method is provided including the processes of: discharging a liquid from discharge holes provided on a liquid-storing unit storing the liquid to make the liquid into droplets, the liquid containing a physiologically active substance and a polymer; and solidifying the droplets into a particle. A61K9/1694 A61K9/1694|G03G9/08755|A61K9/1647|G03G9/0819|A61K31/155|A61K31/55 6 A61K9/16 A61K9/16|A61K31/155|A61K31/55|G03G9/087|G03G9/08 5
303831 dexpanthenol dexpanthenol FDA 승인성분 US US00008906966B2 11/777583 20080125492 8906966 20070713 20080529 20141209 20080529 David Keith Davies|Paul Sherwood Medicaments containing panthenol This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints. A61K31/164 A61K31/164|A61P19/02 2 A61K31/164 A61K31/164|A61P19/02 2
301898 neggram; nalidixic acid [nalidixic acid] neggram; nalidixic acid [nalidixic acid] FDA 승인상품명 US US20140178971A1 14/141571 20140178971 20131227 20140626 20140626 Harvard University Toxin-Eating Bacteria and Bioremediation Bacteria that can use antibiotics as a carbon source are provided. Methods and bacteria useful for bioremediation are also provided. C12N1/205 C12N1/205|C12R2001/01|B08B7/00 3 C12R1/01 C12R1/01 1
301886 natesto [testosterone] natesto [testosterone] FDA 승인상품명 US US20060099667A1 10/532868 20060099667 20031028 20060511 20060511 Cea/Paris|Centre National de laRecherche Scientifique (CNRS) Method for performing restrained dynamics docking of one or multiple substrates on multi-specific enzymes The present invention relates to a method for performing restrained dynamics docking of one or several substrates having allosteric or synergistic effect on enzymes presenting multipspecific and flexible active site. It also concerns a method for determining the 3D-substrates, which is the case for multispecific enzymes such as cytochrome P450, and specifically to cytochrome P450 3A4 and P450 3A7. C12Q1/26 C12Q1/26|G16B15/30|G16B15/00|G01N33/573|G01N2500/00|G01N2333/90245 6 C12N9/02 C12N9/02|C12Q1/26 2
301886,natesto [testosterone],natesto [testosterone],FDA 승인상품명,,,US,US20070135375A1,11/605473,20070135375,,20061129,20070614,,20070614,Ganzer Ursula|Nubbemeyer Reinhard|Wyrwa Ralf,Sulfamoyl sulfonate prodrugs,
The invention relates to sulfamoyl sulfonate prodrugs of general formula I
<chemistry id=CHEM-US-00001 num=1>
<img id=EMI-C00001 he=23.20mm wi=51.90mm file=US20070135375A1-20070614-C00001.TIF alt=embedded image img-content=chem img-format=tif />
</chemistry>
a process for their production, pharmaceutical compositions that contain these compounds, and their use for the production of orally available pharmaceutical agents. The compounds according to the invention bind to carbonic anhydrases and inhibit these enzymes. C07D453/04 C07D453/04|C07H19/12 2 A61K31/7072 A61K31/7072|C07J1/00|C07H19/12|C07D453/04|A61K31/56|A61K31/4745 6
301923 nevirapine [nevirapine] nevirapine [nevirapine] FDA 승인상품명 US US00008212025B2 12/451600 20100125137 8212025 20080514 20100520 20120703 20100520 Aurobindo Pharma Process for preparing nevirapine An improved process for preparing 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one of Formula (I). C07D401/12 C07D401/12|C07D471/14 2 C07D401/12 C07D401/12|C07D471/14 2
301932 niclocide [niclosamide] niclocide [niclosamide] FDA 승인상품명 US US20100285001A1 12/678351 20100285001 20081002 20101111 20101111 University of Rochester Method and Compositions Related to Synergistic Responses to Oncogenic Mutations Disclosed are compositions and methods related to new targets for cancer treatment. C12Q1/6886 C12Q1/6886|C12Q2600/158|G01N33/574|A61P35/00 4 A61K39/395 A61K39/395|A61K38/00|A61P35/00|C12Q1/02|C12Q1/68|C40B30/04|G01N33/53|A61K31/7088 8
301906 neosar [cyclophosphamide] neosar [cyclophosphamide] FDA 승인상품명 US US00005719185B 08/532813 5719185 19951023 19980217 19980217 GlaxoSmithKline (GSK) Use for GABA agonists for treating emesis <p>The present invention relates to the use of GABA agonists having an agonist action at GABA.sub.B receptors in the treatment of emesis.</p> A61K31/195 A61K31/195|A61P25/04|A61P11/00|A61P43/00|A61P35/00 5 A61K31/195 A61K31/195|A61K45/00|A61K31/675|A61K31/70|A61K33/24|A61P25/04|A61P11/00|A61P35/00|A61K31/197|A61P43/00 10
301889 natural estrogenic substance-estrone [estrone] natural estrogenic substance-estrone [estrone] FDA 승인상품명 US US00011353423B2 16/468479 20200150083 11353423 20171222 20200514 20220607 20200514 Vital Biosciences Electrophoresis diagnostic methods and kits The invention described herein provides, in part, improved methods, compositions, and kits for detecting analytes in biological samples. G01N27/44726 G01N27/44726|G01N33/574|G01N33/53|C12Q1/6811|C12P19/34|G01N33/6893 6 G01N27/447 G01N27/447|C12P19/34|C12Q1/6811 3
301890 naturetin [bendroflumethiazide] naturetin [bendroflumethiazide] FDA 승인상품명 US US20060122174A1 11/337872 20060122174 20060123 20060608 20060608 Henderson Morley Research and Development Antiviral treatment A diuretic, e.g. loop diuretic or thiazide, or a sulphylurea is useful in the treatment of DNA viral infections. A61K31/549 A61K31/549|A61K31/426|A61K31/175 3 A61K31/549 A61K31/549|A61K31/426|A61K31/175 3
301891 navane [thiothixene] navane [thiothixene] FDA 승인상품명 US US20140274764A1 13/917573 20140274764 20130613 20140918 20140918 Pathway Genomics METHOD AND SYSTEM TO PREDICT RESPONSE TO TREATMENTS FOR MENTAL DISORDERS The present inventions relates to methods and assays to predict the response of an individual to a psychiatric treatment and to a method to improve medical treatment of a disorder, which is responsive to treatment with a psychiatric treatment. C12Q1/6883 C12Q1/6883|C12Q2600/156|C12Q2600/106|G16H50/30|G16C20/30 5 C12Q1/68 C12Q1/68 1
301891 navane [thiothixene] navane [thiothixene] FDA 승인상품명 US US20200000794A1 16/568666 20200000794 20190912 20200102 20200102 Auspex Pharmaceuticals BENZOQUINOLONE INHIBITORS OF VMAT2 The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. A61K31/473 A61K31/473|A61P25/14|C07C233/18|A61P3/02|A61P29/00|C07D455/06|A61P25/00|C07C217/60|A61P1/16|A61P25/28|C07D221/06|A61P21/00|A61P43/00|A61K45/06|A61P25/24|C07D217/02|A61P19/02|A61P37/02|A61P25/18|C07C291/04|A61P11/06|A61P35/00|C07D471/04 23 A61K31/473 A61K31/473|C07D471/04|C07D455/06|A61K45/06|C07C217/60|C07C233/18|C07C291/04|C07D217/02|C07D221/06 9
303896 dolutegravir sodium dolutegravir sodium FDA 승인성분 US US00009206197B2 14/344737 20140350004 9206197 20120902 20141127 20151208 20141127 Mapi Pharma Amorphous form of dolutegravir An amorphous form of dolutegravir sodium, pharmaceutical compositions comprising same, methods for its preparation and use thereof as an antiretroviral agent. C07D498/14 C07D498/14|A61P31/18|A61P31/12 3 C07D498/14 C07D498/14 1
301896 nedocromil sodium [nedocromil sodium] nedocromil sodium [nedocromil sodium] FDA 승인상품명 US US00005239991B 07/887108 5239991 19920519 19930831 19930831 Fisons Disposable powder medicament inhalation device with peel-off cover <p>A disposable device for the administration of powdered inhalation medicament is provided which comprises a rigid medicament reservoir (4) holding a unit dose of medicament (10) and having air inlet means (5,7) and medicament outlet means (8); and closure means (3) which are removable in use; wherein the medicament (10) held in the reservoir (4) is in loose powder form.</p> A61M15/00 A61M15/00|A61M2202/064 2 B05D7/14 B05D7/14|B65D83/06|A61M16/00|A61M15/00 4
301899 nembutal [pentobarbital] nembutal [pentobarbital] FDA 승인상품명 US US00005134127B 07/469087 5134127 19900123 19920728 19920728 Kansas University Medical Center Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof <p>Sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water insoluble drugs for oral, intranasal, or parenteral administration are disclosed.</p> A61K47/6951 A61K47/6951|C08L5/16|C08B37/0012|B82Y5/00 4 A61K31/715 A61K31/715|C08B37/16|A61K31/71|A61K31/724|A61K47/48|A61K9/18|A61K47/40 7
301899 nembutal [pentobarbital] nembutal [pentobarbital] FDA 승인상품명 US US20160051529A1 14/651351 20160051529 20131205 20160225 20160225 Cirius Therapeutics PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES The present invention relates to PPARy-sparing compounds and pharmaceutical compositions formulated with such compounds that are useful for treating, delaying the onset of, or reducing the symptoms of a neurodegenerative disorder including Huntington's disease, epilepsy, AMS, and MS. A61K31/4439 A61K31/4439|A61K45/06|A61K31/426|A61K31/198|A61P25/28 5 A61K31/4439 A61K31/4439|A61K31/198|A61K45/06 3
301899 nembutal [pentobarbital] nembutal [pentobarbital] FDA 승인상품명 US US00009517269B1 14/617404 9517269 20150209 20161213 20161213 Medtech Products Stable pentobarbital formulation The present invention relates to a pentobarbital formulation with greater stability and fewer impurities. In particular, the formulation may be an aqueous formulation containing 50 mg/mL pentobarbital sodium, 50% glycol, and 10% alcohol, at a pH of 9.4. A61K47/10 A61K47/10|A61K9/0019|A61K31/515|Y02A50/30 4 A61K47/10 A61K47/10|A61K31/515 2
301899 nembutal [pentobarbital] nembutal [pentobarbital] FDA 승인상품명 US US20050186139A1 11/113055 20050186139 20050425 20050825 20050825 Gruenenthal Abuse-proofed dosage form A solid pharmaceutical dosage form that is safeguarded against abuse, comprising at least one active substance that is susceptible to abuse and at least one emetic that is spatially separate from the at least one active substance. The active substance or substances are present in the form of at least one sub-unit (a), and the at least one emetic is present in the form of at least one sub-unit (b), and the emetic from sub-unit (b) is not activated in the body if the dosage form has been correctly administered as prescribed. A61K31/00 A61K31/00|A61K9/1676|A61K9/167|A61K36/74|A61K9/0004|A61K9/209|A61K9/2072 7 A61K9/44 A61K9/44 1
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US00005480779B 08/004643 5480779 19930112 19960102 19960102 Arzneimittelwerk Dresden Cyclosporine assay <p>A process for determining the concentration of cyclosporine in a sample, which comprises adding to the sample a predetermined amount of an isomerase which isomerizes N-terminal peptide to proline, then measuring the enzyme-catalyzed inhibition of the isomerization of a proline- containing substrate, and determining the concentration or cyclosporine from a calibration curve.</p> C12Q1/533 C12Q1/533|C12Q2337/12 2 C12Q1/37 C12Q1/37|C07K5/00|C12Q1/533 3
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US00005585243B 08/120837 5585243 19930915 19961217 19961217 The Blood Center of Southeastern Wisconsin Method of detecting cytopenia that is mediated by drug-dependent antibody binding to blood cells <p>Drug-dependent antibodies that bind to granulocytes, erythrocytes, platelets or membrane proteins derived from these cells, in the presence of a drug, but not in its absence, can be detected using a sensitive assay. Detection of the drug-dependent antibodies permits diagnosis of cytopenia mediated by the drug.</p> G01N33/56972 G01N33/56972|G01N33/56966|G01N33/80 3 G01N33/567 G01N33/567|G01N33/80|G01N33/569 3
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US00007833966B2 11/561912 20070078077 7833966 20061121 20070405 20101116 20070405 Minu|Optivue Enhanced ocular neuroprotection and neurostimulation Use of topically applied cyclosporine to enhance corneal sensitivity restoration rate in an eye of an individual after ocular surgery such as laser-assisted in situ keratomileusis (LASIK) in which nerves are severed. A61K31/192 A61K31/192|A61K31/56|A61K9/0048|A61K31/7048|A61K9/0019|A61K9/0051|A61K31/60|A61P27/02|A61K38/2093|A61P27/06|A61K38/185|A61K31/436|A61K38/13|A61K38/204|A61K31/365 15 A61K38/00 A61K38/00 1
301879 nasacort [triamcinolone acetonide] nasacort [triamcinolone acetonide] FDA 승인상품명 US US00009561336B2 13/380083 20120111327 9561336 20100624 20120510 20170207 20120510 Pfizer Dose unit, pack of dose units and inhaler for inhalation of combination of drugs Various embodiments relate to a dose unit for a dry powder inhaler including: a dose carrier including a plurality of pockets each adapted to contain a dose of medication powder suitable for inhalation, the pockets being sequentially arranged such that the content of the pockets can be sequentially exposed to a flow of air for successive inhalations and a plurality of medication powder doses arranged in the pockets of the dose carrier. The doses are regularly distributed in the pockets according to a sequence of identical groups, each group including at least one blank pocket and one pocket containing a dose of medication powder. Various embodiments also relate to a pack including one such dose unit and one further dose unit with all pockets containing a medication powder. Various embodiments further relate to a dry powder inhaler including such a pack of dose units. A61M15/0045 A61M15/0045|A61M15/0048|A61M15/0051|A61M2202/064|A61M15/0031|A61M15/0003|A61M15/0061 7 A61M15/00 A61M15/00 1
301879 nasacort [triamcinolone acetonide] nasacort [triamcinolone acetonide] FDA 승인상품명 US US00009572859B2 13/857707 20140031298 9572859 20130405 20140130 20170221 20140130 Allergan Compositions and methods for localized therapy of the eye Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers. A61K38/13 A61K38/13|A61K31/00|A61K9/0048|A61P29/00|A61K9/10|A61P27/02|A61K47/36|A61K9/0051|A61K9/14|A61P5/42 10 A61K9/00 A61K9/00|A61K9/14|A61K31/00|A61K38/13|A61K47/36|A61K9/10 6
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US00009308124B2 12/340095 20090240215 9308124 20081219 20090924 20160412 20090924 University of Southern California (USC) Apparatus and methods for delivering therapeutic agents In various embodiments, a drug-delivery device includes one or more reservoirs that may each contain a therapeutic agent for delivery to a patient. A61F9/0017 A61F9/0017|A61P27/06|A61P27/14|A61P27/02|A61P43/00|A61F2250/0068|A61P35/00|A61P29/00|A61P31/22|A61P25/00|A61P25/28|A61M31/002|A61F9/0026 13 A61F9/00 A61F9/00|A61M31/00|A61M35/00 3
301935 nifedipine [nifedipine] nifedipine [nifedipine] FDA 승인상품명 US US20070191371A1 11/675067 20070191371 20070214 20070816 20070816 Kalypsys HETEROCYCLIC MODULATORS OF PPAR The present invention relates to compounds and methods useful as modulators of Peroxisome Proliferator-Activated Receptors (PPARs) for treatment or prevention of disease. A61K31/381 A61K31/381|A61K31/4965|A61K31/53|A61K31/4439|A61K31/501|A61K31/4192|A61K31/50|A61K31/4164|A61K31/497|A61K31/4152|A61K45/06 11 A61K31/53 A61K31/53|A61K31/4164|A61K31/4152|A61K31/381|A61K31/501|A61K31/4192|A61K31/50|A61K31/497|A61K31/4965|A61K31/4439 10
303618 ceftazidime ceftazidime FDA 승인성분 US US00008309590B2 12/600667 20100152101 8309590 20080521 20100617 20121113 20100617 Novartis Triazol compounds for treating biofilm formation The present invention relates to the use of a Compound of formula I A61K31/4196 A61K31/4196|A61P11/00|A61K45/06|A61P31/04 4 A61K31/41 A61K31/41|A61K31/545|A61K31/7048|A61K31/546|A61K31/5383|A61K31/496|A61K31/4196|A61K31/397|A01N43/64|A61K38/00|A61P31/04|A61P11/00|A61K38/12 13
303618 ceftazidime ceftazidime FDA 승인성분 US US00008501457B2 13/155469 20120052555 8501457 20110608 20120301 20130806 20120301 Hanwha Aerospace Enrichment of Listeria spp A medium for enriching <i>Listeria </i>spp. without polymerase chain reaction (PCR) inhibition and a method of using the medium. C12N1/20 C12N1/20 1 C12N1/20 C12N1/20 1
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US20120010131A1 12/981695 20120010131 20101230 20120112 20120112 Scynexis NOVEL CYCLOSPORIN ANALOGUES The invention relates to the use of cyclic compounds of general formula (I): C07K7/645 C07K7/645|A61P31/12|A61K38/00|A61P31/14 4 A61K38/13 A61K38/13|C07K7/64|C12N5/071|A61P31/14 4
301930 niacin; niacor; niaspan; nicolar [niacin] niacin; niacor; niaspan; nicolar [niacin] FDA 승인상품명 US US00009145426B2 14/009654 20140023667 9145426 20120402 20140123 20150929 20140123 MSD (Merck & Company) Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): C07D513/04 C07D513/04|A61K31/549|A61P25/00|A61K45/06 4 C07D513/04 C07D513/04|A61K45/06|A61K31/549 3
301879 nasacort [triamcinolone acetonide] nasacort [triamcinolone acetonide] FDA 승인상품명 US US00009597396B2 14/142178 20140171398 9597396 20131227 20140619 20170321 20140619 Mylan Specialty Formoterol/steroid bronchodilating compositions and methods of use thereof Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided. A61K47/10 A61K47/10|A61P11/08|A61K31/568|A61P11/06|A61K31/58|A61K47/02|A61K31/191|A61K31/56|A61K45/06|A61K31/537|A61K31/167|A61P43/00|A61K9/0078|A61K31/573|A61P11/00 15 A61K31/58 A61K31/58|A61K9/00|A61K31/167|A61K31/573|A61K31/56|A61K47/02|A61K31/568|A61K45/06|A61K31/537|A61K47/10|A61K31/191|A61K31/135 12
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US00010953073B2 16/133444 20190083577 10953073 20180917 20190321 20210323 20190321 Amunix Pharmaceuticals XTEN conjugate compositions and methods of making same The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions. A61K38/24 A61K38/24|A61P37/02|A61P35/00|A61P27/00|A61P25/04|C07K5/0205|A61P11/00|A61P9/00|A61P29/00|A61P19/00|A61P13/12|A61P3/00|A61P1/00|A61P25/00|A61K47/64|A61P5/00|A61K49/0052|A61K49/0032|A61P31/18|A61P31/00|A61K49/0056 21 A61K38/24 A61K38/24|A61K47/64|C07K5/02|A61K49/00 4
301925 nexcede [ketoprofen] nexcede [ketoprofen] FDA 승인상품명 US US00006245802B1 09/438191 6245802 19991111 20010612 20010612 Eli Lilly and Company Method for treating pain <p>The present invention provides a method for treating pain comprising administering to a mammal an analgesic composition comprising duloxetine and one or more NSAIDs or acetaminophen.</p> A61K31/415 A61K31/415|A61K45/06|A61P25/04|A61P29/00|A61P43/00|A61K31/38|A61K31/40|A61K31/405|A61K31/60 9 A61K31/381 A61K31/381|A61K45/06|A61P43/00|A61P25/04|A61K31/192|A61K31/38|A61K31/405|A61K45/00|A61K31/60|A61P29/00|A61K31/415|A61K31/40 12
301925 nexcede [ketoprofen] nexcede [ketoprofen] FDA 승인상품명 US US000RE045548E1 14/049262 RE45548 20131009 20150609 20150609 Bezwada Biomedical Functionalized drugs and polymers derived therefrom Compounds selected from: A61K9/1647 A61K9/1647|A61K31/00|A61K31/185|A61K47/48007|C08L67/04|A61K31/7135|A61K31/05|A61L31/10|A61K31/192|A61K31/535|A61K31/381|C07C69/734|C07C69/92|A61K31/439|A61K31/47|A61K9/0058|A61K31/343|A61K31/352|A61K31/4164|C08G18/711|A61K31/428|A61K31/485|A61K31/445|A61K31/353|A61K31/404|C08G18/771|A61K31/405|C08G18/3206|C08G18/797 29 A61K9/14 A61K9/14|A61K47/48|A61K9/16 3
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US20090232731A1 12/300448 20090232731 20070518 20090917 20090917 MediGene Cationic Liposomal Preparations for the Treatment of Rheumatoid Arthritis The present invention refers to the use of cationic liposomal preparations for the treatment or diagnosis of rheumatoid arthritis or related disorders. A61K31/337 A61K31/337|A61P19/02|A61K31/519|A61K9/1271|A61K9/0019 5 A61K51/00 A61K51/00|A61K49/00|A61K31/519|A61K9/127|A61K31/337 5
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US20080076827A1 11/575995 20080076827 20051020 20080327 20080327 Sosei R&D Treatment of Inflammatory Bowel Disease Actarit or a salt thereof is useful for the treatment of inflammatory bowel disease. A61K31/196 A61K31/196|A61P1/04|A61P1/00 3 A61K31/19 A61K31/19|A61P1/00 2
303626 celecoxib celecoxib FDA 승인성분 US US20050191343A1 10/995942 20050191343 20041124 20050901 20050901 Supernus Pharmaceuticals Micellar systems useful for delivery of lipophilic or hydrophobic compounds The present invention is directed to reverse micellar formulations for the delivery of hydrophobic or lipophilic compounds, particularly therapeutic compounds. A61K9/107 A61K9/107|A61K47/14|A61K47/10|A61K47/40 4 A61K9/127 A61K9/127 1
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US20130004516A1 13/582179 20130004516 20110303 20130103 20130103 Sumitomo Dainippon Pharma DRUG FOR INFLAMMATORY BOWEL DISEASE Anti-CD81 antibody displays not only a remission induction effect, but also a long-term remission maintenance effect on inflammatory bowel disease when administered in a single dose, and is therefore effective as a drug for maintaining remission from inflammatory bowel disease. Moreover, anti-CD81 antibody is effective as a drug for the prevention, amelioration and treatment of inflammatory bowel disease because it has preventive, therapeutic and ameliorating effects on refractory inflammatory bowel disease. C07K16/2896 C07K16/2896|A61K2039/505|A61P1/04|A61P1/00|A61K2039/545 5 A61K39/395 A61K39/395|A61P1/00|A61P1/04 3
301935 nifedipine [nifedipine] nifedipine [nifedipine] FDA 승인상품명 US US00005725871B 08/260611 5725871 19940615 19980310 19980310 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Drug delivery compositions comprising lysophosphoglycerolipid <p>Compositions for trans-mucosal delivery, e.g. intranasal, include a lysophosphatidyl-glycerol compound as the adsorption enhancer. The preferred compounds for delivery are insulin and calcitonin.</p> A61K47/24 A61K47/24|A61K9/0043|A61K9/0034 3 A61K9/08 A61K9/08|A61K9/16|A61K38/00|A61K47/24|A61K9/00 5
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US20140094426A1 14/076001 20140094426 20131108 20140403 20140403 Commonwealth Scientific and Industrial Research Organisation (CSIRO) AMPHIPHILE PRODRUGS Amphiphilic prodrugs of general formula A-X are disclosed, wherein A is a biologically active agent or may be metabolized to a biologically active agent; and X is R, or up to three R moieties attached to a linker, Y<sub>1</sub>, Y<sub>2 </sub>or Y<sub>3</sub>. Self-assembly of the amphiphilic prodrugs into reverse lyotropic phases, particularly hexagonal, cubic and sponge, is disclosed. C07H19/02 C07H19/02|A61K47/54|A61K9/146|C07H19/067|A61K9/107|C07C233/18|A61P35/00 7 A61K47/48 A61K47/48|C07C233/18|C07H19/02 3
301925 nexcede [ketoprofen] nexcede [ketoprofen] FDA 승인상품명 US US20050119262A1 10/919835 20050119262 20040817 20050602 20050602 Pharmacia & Upjohn Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent The present invention provides methods and compositions for the prevention and/or treatment of an optic neuropathy, comprising a Cox-2 inhibitor and an intraocular pressure reducing agent. A61K45/06 A61K45/06|A61K31/5377|A61K31/535|A61K31/415|A61K31/137|A61K31/557 6 A61K31/5377 A61K31/5377|A61K31/415|A61K31/557|A61K31/137 4
301905 neoral [cyclosporine] neoral [cyclosporine] FDA 승인상품명 US US20170136065A1 15/323371 20170136065 20150630 20170518 20170518 Takeda Pharmaceutical MESENCHYMAL STROMAL CELLS FOR TREATING RHEUMATOID ARTHRITIS The present invention provides a method for treating rheumatoid arthritis comprising the use of mesenchymal stromal cells. A61K35/28 A61K35/28|A61P29/00|A61P19/02|A61P9/02|A61K38/13 5 A61K35/28 A61K35/28|A61K38/13 2
301906 neosar [cyclophosphamide] neosar [cyclophosphamide] FDA 승인상품명 US US00006096757B 09/217335 6096757 19981221 20000801 20000801 MSD (Merck & Company) Method for treating proliferative diseases <p>Methods are provided for treating proliferative diseases, especially cancers, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an antineoplastic agent and/or radiation therapy.</p> A61K31/505 A61K31/505|A61K31/675|A61K31/53|A61K31/475|A61K31/445 5 A61K31/44 A61K31/44|A61K31/505|A61K31/675|A61K31/53|A61K31/475|A61K31/445 6
302087 ovide [malathion] ovide [malathion] FDA 승인상품명 US US20060130266A1 10/543799 20060130266 20041216 20060622 20060622 Brown Marc B|Martin, Gary P Dermal drug delivery system A device for brushing the skin prior to applying a topical preparation of a drug enhances the permeability of the stratum corneum to the drug. A61B17/20 A61B17/20|A61B17/205|A61H7/002|A61B2017/320012|A61B2017/00761 5 A47L5/00 A47L5/00 1
301906 neosar [cyclophosphamide] neosar [cyclophosphamide] FDA 승인상품명 US US00006214863B1 09/371520 6214863 19990810 20010410 20010410 Aventis Pharma Antitumor compositions containing taxane derivatives <p>Disclosed are combinations of a taxoid, an alkylating agent and an anthracycline antibiotic, which compositions exhibit therapeutic synergy in the treatment of cancer.</p> A61K31/4745 A61K31/4745|A61K33/243|C07D305/14|A61K31/525|A61K38/21|A61K31/675|A61K45/06|A61K31/335|A61K31/7072|A61P35/02|A61K31/505|A61K38/20|C12Y305/01001|A61K31/66|A61K38/50|A61K31/7048|A61P35/00|A61K31/337 18 A61K31/335 A61K31/335|A61K31/66|A61K31/4745|A61K33/24|C07D305/14|A61K31/7048|A61K45/06|A61K31/7072|A61K31/337|A61P35/00|A61K31/505|A61K31/675|A61K38/43|A61K31/525 14
303639 cetyl alcohol cetyl alcohol FDA 승인성분 US US20120101118A1 13/277828 20120101118 20111020 20120426 20120426 Purdue Pharma TAMPER RESISTANT DOSAGE FORMS Tamper resistant controlled release formulations. A61K9/2054 A61K9/2054|A61K9/2095|A61K9/1694|A61K9/2013|A61P25/36|A61P25/04|A61K31/485 7 A61K31/485 A61K31/485|A61P25/04 2
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US00006528682B1 09/959183 6528682 20011018 20030304 20030304 Medichem Process for producing gabapentin or pharmaceutical grade <p>The invention describes a process for the preparation of pharmaceutical grade gabapentin, consisting of neutralizing an alcoholic solution of gabapentin hydrochloride with basic ion exchange resins and thereafter directly isolating the gabapentin, without requiring either the formation or the isolation of intermediates other than the pharmaceutical grade product.</p> C07C227/40 C07C227/40|C07C2601/14 2 A61K31/195 A61K31/195|C07C229/00|C07C227/40|C07C229/28 4
301918 neuramate [meprobamate] neuramate [meprobamate] FDA 승인상품명 US US20060014697A1 11/089056 20060014697 20050325 20060119 20060119 Shire Pharmaceutical compositions for prevention of overdose or abuse The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. C07K5/06086 C07K5/06086|C07K5/0808|A61K47/549|A61P25/30|A61K47/542|A61K38/00|A61P25/00|C07K7/06|A61P3/04|C07K5/1008|A61K47/64 11 A61K38/08 A61K38/08|C07K7/06 2
301918 neuramate [meprobamate] neuramate [meprobamate] FDA 승인상품명 US US20120095104A1 13/118563 20120095104 20110530 20120419 20120419 Zachar, Oron USE OF VASOCONSTRICTORS There is disclosed the topical dermal use of vasocontrictor substances for regulating body temperature to treat, prevent or delay the onset of anesthetic induced hypothermia. Kits containing appropriate materials and instructions, and other embodiments, are also disclosed. A61F7/00 A61F7/00|A61K36/00|A61F2007/0045|A61K36/9068|A61K31/165|A61F2007/0036|A61K36/81|A61K31/137|A61P39/00|A61K36/752|A61K9/0014|A61P9/00|A61K36/17|A61K45/06 14 A61K31/137 A61K31/137|A61P39/00|A61P9/00|A61K31/165 4
301918 neuramate [meprobamate] neuramate [meprobamate] FDA 승인상품명 US US20130116215A1 13/660205 20130116215 20121025 20130509 20130509 Anaxomics Biotech COMBINATION THERAPIES FOR TREATING NEUROLOGICAL DISORDERS The invention features novel pharmaceutical combinations useful for the treatment of neurological diseases, specifically neurodegenerative diseases. The novel pharmaceutical combinations of the invention demonstrate additive or synergistic effect in silico and in vivo. The invention also relates to methods of treatment of neurological and neurodegenerative diseases including the pharmaceutical combinations of the invention. A61K45/06 A61K45/06|A61K31/165|A61K31/48|A61K31/4045|A61K31/56|A61K31/4422|A61K31/40|A61K31/549|A61K31/4406|A61K31/337|A61K31/5377|A61K31/428|A61K31/663|A61K31/196|A61K31/51|A61K31/4174|A61K31/655 17 A61K45/06 A61K45/06|A61K31/40|A61K31/337|A61K31/196|A61K31/165|A61K31/655|A61K31/56|A61K31/549|A61K31/5377|A61K31/663|A61K31/4045|A61K31/4174|A61K31/428|A61K31/4406|A61K31/4422|A61K31/51|A61K31/48 17
301935 nifedipine [nifedipine] nifedipine [nifedipine] FDA 승인상품명 US US00006221368B1 09/254558 6221368 19990310 20010424 20010424 AbbVie Process for producing solid dosage forms by extrusion <p>A process for producing solid dose forms by mixing at least one polymeric binder, with or without at least one active ingredient and with or without conventional additives, and shaping the mixture, where at least one of the components is employed in liquid form.</p> A61K9/2095 A61K9/2095|A61K9/2086|A61K9/2027 3 A61K9/00 A61K9/00|A61J3/00|A61K9/16|A61K9/20 4
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US00006881843B2 10/455314 20030195358 6881843 20030606 20031016 20050419 20031016 Teva Pharmaceutical Industries Process for production of gabapentin intermediate The invention relates to a novel process for producing a the intermediary compound α,α′,dicyano-β,β-pentamethyleneglutarimide. The process includes the steps of reacting a ketone such as cyclohexanone with ethylcyanoacetate in the presence of ammonium hydroxide. C07D221/20 C07D221/20 1 C07D221/20 C07D221/20|C07C233/00 2
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US00008299291B2 12/537798 20100087667 8299291 20090807 20100408 20121030 20100408 ARBOR PHARMACEUTICALS Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs The present disclosure relates to methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs and to intermediates used in the methods. C07C269/04 C07C269/04|C07C319/20|C07C315/02|C07C2601/14|C07C323/20|C07C317/22 6 C07C269/06 C07C269/06|C07C69/96 2
301965 noroxin [norfloxacin] noroxin [norfloxacin] FDA 승인상품명 US US00010689370B2 16/225098 20190367492 10689370 20181219 20191205 20200623 20191205 Auspex Pharmaceuticals Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof. C07D405/12 C07D405/12|A61K31/497|A61P11/00 3 C07D405/12 C07D405/12|A61K31/497|A61P11/00 3
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US00011446268B2 16/778334 20200246296 11446268 20200131 20200806 20220920 20200806 Yamo Pharmaceuticals Compositions and methods for treating anxiety-related disorders The present invention provides methods, compositions, and kits for treating anxiety-related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof. A61K31/198 A61K31/198|A61K9/0053|A61K9/48|A61K31/197|A61K31/4045|A61K38/095|A61K45/06|A61P25/22 8 A61P25/22 A61P25/22|A61K9/20|A61K31/192|A61K31/195|A61K31/197|A61K31/4045|A61K31/198|A61K9/00|A61K45/06|A61K38/095 10
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US20120083508A1 13/295933 20120083508 20111114 20120405 20120405 Allergan ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an alpha-2B receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed. A61K45/06 A61K45/06|A61P29/00|A61K31/197|A61P25/08|A61K31/195|A61K31/4709|A61K31/4174|A61P29/02|A61K31/4164 9 A61K31/4709 A61K31/4709|A61K31/421|A61K31/4168|A61K31/197|A61K31/4164|A61P29/00|A61P25/08 7
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US20130142882A1 13/677217 20130142882 20121114 20130606 20130606 Golden Biotechnology METHODS AND COMPOSITIONS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF BONE CANCER PAIN The present invention provides methods and compositions for treating, preventing, modifying (reducing), or managing bone cancer pain by cyclohexenone compounds. A61K31/122 A61K31/122|A61K9/4858|A61P25/04|A61K9/0019|A61K31/34|A61K9/0078|A61P19/08|A61K9/0014|A61K31/19|A61K9/0056|A61K45/06|A61K31/133|A61P35/00|A61K9/0048|A61K31/7028|A61K9/4866|A61P29/00|A61K9/0031|A61K31/366 19 A61K31/122 A61K31/122|A61K31/19|A61K45/06 3
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US20140072623A1 14/075965 20140072623 20131108 20140313 20140313 Assertio Therapeutics GASTRIC RETAINED GABAPENTIN DOSAGE FORM A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. A61K9/0065 A61K9/0065|A61K9/2054|A61K9/0002|A61P25/14|A61P25/00|A61K9/2031|A61P25/08|A61K45/06|A61P29/00|A61P25/06|A61K31/197|A61P25/24|A61P25/04|A61K9/48|A61K31/195|A61P25/18|A61P25/02 17 A61K9/00 A61K9/00|A61K45/06|A61K31/197 3
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US20160263044A1 15/163491 20160263044 20160524 20160915 20160915 Assertio Therapeutics METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. A61K9/2866 A61K9/2866|A61K9/284|A61K9/0004|A61P25/14|A61M31/002|A61K9/2054|A61P25/08|A61K45/06|A61K9/2031|A61P25/06|A61K31/195|A61P29/00|A61P25/02|A61K9/48|A61K9/0065|A61P25/18|A61P25/00 17 A61K9/28 A61K9/28|A61K9/00|A61K31/195|A61K45/06 4
301920 neurontin [gabapentin] neurontin [gabapentin] FDA 승인상품명 US US20170143681A1 15/341700 20170143681 20161102 20170525 20170525 Apkarian Technologies METHODS AND COMPOSITIONS FOR TREATING PAIN The invention features combinations of dopaminergic agents and analgesic agents useful for treating pain. In particular, the combinations feature a low ratio of dopaminergic agent to analgesic agent. The dopaminergic agent can be an agonist of the dopamine receptor D1-like family or the dopamine receptor D2-like family. Such combinations potentiate analgesia to 1) alleviate acute pain, 2) prevent the transition from acute pain to chronic pain, and 3) manage chronic pain. A61K31/428 A61K31/428|A61K45/06|A61K31/198|A61K31/192|A61K31/167 5 A61K31/428 A61K31/428|A61K31/167|A61K31/192|A61K31/198 4
301922 nevanac [nepafenac] nevanac [nepafenac] FDA 승인상품명 US US20150335704A1 14/719157 20150335704 20150521 20151126 20151126 Harrow Ip PHARMACEUTICAL COMPOSITIONS COMPRISING GELS AND METHODS FOR FABRICATING THEREOF Pharmaceutical compositions are described, the compositions comprising a therapeutically effective quantity of an active component and a quantity of a sterile gel. Methods for fabricating the compositions and using them for ophthalmic or burn-treating applications are also described. A61K9/0048 A61K9/0048|A61K47/10|A61K31/5377|A61K45/06|A61K9/06|A61K38/14|A61K31/7036|A61K47/34|A61K31/5575 9 A61K31/7036 A61K31/7036|A61K38/14|A61K9/00 3
301941 nipride; nitropress [sodium nitroprusside] nipride; nitropress [sodium nitroprusside] FDA 승인상품명 US US00005912019B 08/951262 5912019 19971016 19990615 19990615 Medical University of South Carolina (MUSC) Compounds for reducing ischemia/reperfusion injury <p>Disclosed herein are compositions containing NO donors, inhibitors of iNOS induction, and endopeptidase inhibitors, and methods for their use for combating injury induced by ischemia and reperfusion following ischemic episodes.</p> A61K33/00 A61K33/00|A61K33/26 2 A61K31/195 A61K31/195|A61K31/35|A61K33/26|A61K31/675|A61K33/00 5
301923 nevirapine [nevirapine] nevirapine [nevirapine] FDA 승인상품명 US US00007186736B1 09/272821 7186736 19990320 20070306 20070306 Uckun, Fatih, M NNI for treatment of multi-drug resistant HIV The present invention is directed to compounds and methods suitable for the treatment of HIV infection. A61K31/17 A61K31/17|A61P31/18 2 A61K31/44 A61K31/44|A61K31/17|A61P31/18 3
301951 nogenic hc; nutracort [hydrocortisone] nogenic hc; nutracort [hydrocortisone] FDA 승인상품명 US US20070112018A1 11/543595 20070112018 20061005 20070517 20070517 Activbiotics Pharma Treatment of peripheral arterial occlusive disease The invention relates to the treatment of peripherial arterial occlusive disease. A61K31/4745 A61K31/4745|A61P9/00|A61K45/06|A61K31/343 4 A61K31/4745 A61K31/4745 1
301940 nipent [pentostatin] nipent [pentostatin] FDA 승인상품명 US US20060088899A1 10/516079 20060088899 20030602 20060427 20060427 Eisai Combination chemotherapy with chlorotoxin This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof. A61K31/522 A61K31/522|A61K45/06|A61K38/17|A61K38/16|A61K31/7048|G01N33/57407 6 C12Q1/58 C12Q1/58|A61K31/522|A61K31/7048|A61K38/16 4
303952 epinephrine epinephrine FDA 승인성분 US US00004066769B 05/753719 4066769 19761223 19780103 19780103 Pharmacia & Upjohn 3,3'-(2,6-PYRIDINEDIYL-5-ISOXAZOLE CARBOXYLIC ACIDS, SALTS, AND ESTERS, COMPOSITIONS AND METHODS OF USE THEREOF <p>Novel compounds of the formula ##STR1## wherein X is hydrogen, alkyl of one to six carbon atoms, inclusive, alkoxy of one to six atoms, inclusive, phenyl, cyano, nitro, trifluoromethyl, fluoro, chloro or bromo; &lt;P&gt;&lt;P&gt;R is hydrogen, alkyl of one to eight carbon atoms, inclusive, and a physiologically acceptable metal or amine cation and novel compositions wherein R is hydrogen or a physiologically acceptable metal or amine cation are used for prophylactically treating allergic disorders such as asthma.&lt;P&gt;&lt;P&gt;BRIEF SUMMARY OF THE INVENTION&lt;P&gt;&lt;P&gt;It has now been discovered that novel compounds of Formula I are useful in the prophylactic treatment of sensitized humans and animals for allergy and anaphylactic reactions of a reagin or non-reagin mediated nature. The compounds are formulated with pharmaceutical carriers for oral, parenteral, inhalation or rectal means of administration.&lt;P&gt;&lt;P&gt;DETAILED DESCRIPTION OF THE INVENTION ##STR2## wherein X is hydrogen, alkyl of one to six carbon atoms, inclusive, alkoxy of one to six carbon atoms, inclusive, phenyl, cyano, nitro, trifluoromethyl, fluoro, chloro or bromo;&lt;P&gt;&lt;P&gt;R is hydrogen, alkyl of one to eight carbon atoms, inclusive, and a physiologically acceptable metal or amine cation.&lt;P&gt;&lt;P&gt; Another group of compounds, hereafter referred to as Group B, are those compounds of Group A wherein R is hydrogen, alkyl of one to six carbon atoms, inclusive, or a physiologically acceptable metal or amine cation; X is hydrogen, alkyl of one to four carbon atoms, inclusive, alkoxy of one to four carbon atoms, inclusive, phenyl, cyano, nitro, trifluoromethyl, fluoro, chloro and bromo.&lt;P&gt;&lt;P&gt;A further group of compounds, hereafter referred to as Group C, are those compounds of Group B wherein R is hydrogen, alkyl of one to three carbon atoms, inclusive, or a physiologically acceptable metal or amine cation; X is hydrogen, alkyl of one to three carbon atoms, inclusive, alkoxy of one to three carbon atoms, inclusive, phenyl, cyano, trifluoromethyl, fluoro, chloro or bromo.&lt;P&gt;&lt;P&gt;Another group of compounds, hereafter referred to as Group D, are those compounds of Group C wherein X is hydrogen, alkyl of one to three carbon atoms, inclusive, alkoxy of one to three carbon atoms, inclusive, cyano thrifluoromethyl, fluoro and chloro. &lt;P&gt;&lt;P&gt;A further group of compounds are those compounds of Group D wherein X is at the four position.&lt;P&gt;&lt;P&gt;The tris(hydroxymethyl)aminomethane salt of the compound of the formula wherein X is hydrogen is preferred.&lt;P&gt;&lt;P&gt;As employed in the above disclosure and throughout the specification and claims, the phrase alkyl of one to eight carbon atoms, inclusive includes methyl, ethyl, propyl, butyl pentyl, hexyl, heptyl, octyl and isomers thereof. Illustrative examples of isomers are isopropyl, tert.butyl, neopentyl, 2, 2-dimethylbutyl, 2-methylhexyl, and 2,2,4-trimethylphentyl. Alkyl of a smaller number of carbon atoms has a similar scoping.&lt;P&gt;&lt;P&gt; The phrase physiologically acceptable amine salt refers to amines which are accepted by mammals in an essentially non-toxic manner when administered to mammals in conjunction with the acid moiety of the invention. Illustrative of the amines are those derived from primary, secondary or tertiary amines. Examples of suitable amines are methylamine, dimethylamine, triethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, &agr;-phenylethylamine, &bgr;-phenylethylamine, ethylenediamine, diethylenetriamine, adamantylamines, and like aliphatic, cycloaliphatic, and araliphatic amines containing up to and including about eighteen carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g., 1-methylpiperidine, 4-ethylmorpholine, 1- isopropylpyrrolidine, 2-methylpyrrolidine, 1,4-dimethylpiperazine, 2- methylpiperidine, and the like, as well as amines containing water- solubilizing or hydrophilic groups, e.g., mono-, di-, and triethanolamine, ethyldiethanolamine, N-butylethanolamine, 2-amino-1-butanol, 2-amino-1- ethyl-1,3-propanediol, 2-amino-2-methyl-1-propanol, tris(hydroxymethyl) aminomethane, N-phenylethanolamine, N-(p-tert-amylphenyl)diethanolamine, galactamine, N-methylglucamine, N-methylglucosamine, ephedrine, phenylephrine, epinephrine, procaine, and the like. Also included within the amine scope are quaternary amines such as ammonium, tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, phenyltriethylammonium, and the like.&lt;P&gt;&lt;P&gt;The term physiologically acceptable metal includes alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, and other acceptable metals such as aluminum.&lt;P&gt;&lt;P&gt;The compounds of the invention can be prepared by methods known in the art.&lt;P&gt;&lt; P&gt;With respect to the 5-isoxazole carboxylates, acids and salts thereof, the appropriately substituted pyridine dialdehyde (II) is a suitable starting material. These compounds are reacted with an acid addition salt of hydroxylamine, for example, hydroxylamine hydrochloride (III) under standard conditions to form a dioxime (IV). The dioxime is then reacted with a halogen such as chlorine or bromine in an inert organic solvent at a low temperature to form the &agr;,&agr;- dihalopyridyl-dioxime (V). The product of Formula V is then reacted with an alkyl propiolate (VI) in organic solvent containing an organic base to form the 5-isoxazolecarboxylate. ##STR3##&lt;P&gt;&lt;P&gt;The esters of Formula VII are readily transesterified to other esters of Formula I or converted to the acid or a physiologically acceptable salt by standard methods.&lt;P&gt;&lt;P&gt;In preparing the 5-isoxazolecarboxylates, the appropriately X substituted aldehydes are prepared by conventional substitution methods. Depending upon the substituent itself, the placement of the aldehyde group, the substitution of the pyridine ring can occur on pyridine itself, pyridine aldehyde, or the pyridine dialdehyde, depending upon the orientation direction effect of the substituent. The appropriately substituted starting material is then reacted with an acid addition salt of hydroxylamine under standard conditions to form the pyridine dioxime. The dioxime is then reacted with a halogen gas, preferably chlorine in an organic solvent inert to the gas of a low temperature to form the &agr;,&agr;-dihalopyridyldioxime. Halogenated solvents such as carbon tetrachloride, chloroform and methylene chloride are suitable solvents for the halogenation step. The temperature of the reaction should be maintained from 0&deg; to about 30&deg; C., preferably from 0 to about 15&deg; C. The &agr;,. alpha.- dihalogenated dioxime is then reacted with an alkyl propiolate, alkyl having one to six carbon atoms, inclusive, in an organic solvent and an amine to form the 5-isoxazolecarboxylate. Suitable organic solvents are lower alcohols such as methanol, ethanol, propanol and the like, and cyclic ethers such as tetrahydrofuran and 1,4-dioxane. Suitable amines functioning as an acid scavenging agent are triethylamine, tripropylamine, and higher trialkylamines, 1-methylpiperidine, 1- methylpyrrolidine, 1,4- dimethylpiperazine and the like.&lt;P&gt;&lt;P&gt; The diesters are then converted to the diacids by alkaline hydrolysis with a base such as sodium hydroxide followed by treatment with an acid such as hydrochloric acid. The acid is then readily converted into any of the physiologically acceptable metal or amine salts.&lt;P&gt;&lt;P&gt; Following are illustrative examples of compounds of the invention which can be prepared by the known procedures. ##TBL1##&lt;P&gt;&lt;P&gt;TABLE II&lt;P&gt;&lt; P&gt;The compounds of Table I are converted to esters wherein R is alkyl of one to eight carbon atoms, inclusive, other than ethyl. Examples of such esters are methyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomers thereof.&lt;P&gt;&lt;P&gt;TABLE III&lt;P&gt;&lt; P&gt;The compounds of Table I are converted to the diacids by standard methods.&lt; P&gt;&lt;P&gt;TABLE IV&lt;P&gt;&lt;P&gt;The compounds of Table III are converted to physiologically acceptable salts of the acid, preferably sodium, potassium and tris(hydroxymethyl)aminomethane.&lt;P&gt; &lt;P&gt; Table II, III and IV are not rendered in the same manner as Table I for the purpose of brevity. However, the same scoping is intended. </p> C07D213/78 C07D213/78 1 C07D413/14 C07D413/14|C07D213/78 2
301925 nexcede [ketoprofen] nexcede [ketoprofen] FDA 승인상품명 US US00004599359B 06/668896 4599359 19841107 19860708 19860708 Cooper; Stephen A. HYDROXYZINE-CONTAINING ANALGESIC COMBINATIONS <p>Hydroxyzine or it's therapeutically acceptable, non-toxic salts, in combination with a non-steroidal, anti-inflammatory agent are effective analgesic compositions.</p> A61K31/495 A61K31/495|A61K31/505|A61K31/60 3 A61K31/19 A61K31/19|A61K31/495|A61K31/505 3
301925 nexcede [ketoprofen] nexcede [ketoprofen] FDA 승인상품명 US US00005204119B 07/748208 5204119 19910820 19930420 19930420 Kasai; Masayoshi|Konita; Takeshi|Nonaka; Jun|Shiobara; Takao External preparation comprising calcium silicate <p>An external preparation is characterized by comprising calcium silicate. The calcium silicate controls the release rate and percutaneous absorbability of a drug.</p> A61K31/19 A61K31/19|A61K9/143|A61K31/405 3 A61K9/14 A61K9/14|A61K31/405|A61K47/02|A61K31/19 4
301925 nexcede [ketoprofen] nexcede [ketoprofen] FDA 승인상품명 US US00005654004B 08/432202 5654004 19950505 19970805 19970805 Hisamitsu Pharmaceutical Oral pharmaceutical preparation releasable in the lower digestive tract <p>An oral pharmaceutical preparation releasable in the lower digestive tract, characterized by having a double-coated structure wherein a solid drug having a core containing an active ingredient is covered with both an inner coat made of a cationic polymer and an outer coat made of an anionic polymer.</p> A61K9/5073 A61K9/5073|A61K9/2018|A61K9/2886 3 A61K9/32 A61K9/32|A61K9/30|A61K9/28|A61K9/50|A61K9/20 5
상품 미리보기
연락처 및 데이터 관리
판매제공처 홈페이지 판매담당자 연락처 이메일
 www.BLT.kr 특허법인BLT 02-514-0104  khpark@blt.kr
제약 및 취소환불 규정
제약 및 취소/환불 규정 안내
데이터 상품은 디지털화된 상품의 특성상 반품, 취소, 환불 되지 않으나 데이터의 심각한 오류, 상이한 데이터에 한하여 구매자가 요구하는 경우 환불을 진행할 수 있습니다.
상품 Q&A

※ 본인의 글만 수정이 가능하며, 타인의 글에 댓글을 남길 수 없습니다.
※ 댓글이 달린 글은 수정과 삭제가 불가능합니다.

등록된 글이 없습니다.

닫기버튼
해당 문의 내역을 삭제하시겠습니까?

닫기버튼
해당 문의 내역을 삭제하시겠습니까?